Important data reveals are expected from Madrigal, Arrowhead and Ascendis, with details from Biogen and Eisai due at a conference.
The group gets a win in severe hypertriglyceridaemia, but a bigger readout in Nash awaits.
ILT3 blockade shows no monotherapy activity while a combo runs into toxicity issues, but Merck presses on.
Pivotal development of GEM103 is set to proceed, but the phase 2 result is a cautionary tale – not only for Gemini.
The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.
As semaglutide looks set to move into pivotal trials in Nash, Novo Nordisk lays out hopes for longer-term benefits.
Before Covid-19 came along investors were looking to several Nash catalysts in 2020, and yesterday Akero delivered on one of these.